Back to top
more

Bioventus (BVS)

(Delayed Data from NSDQ)

$3.98 USD

3.98
128,404

-0.09 (-2.21%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $3.98 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value A Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 36% (91 out of 252)

Industry: Medical - Drugs

Better trading starts here.

Zacks News

PTC Therapeutics (PTCT) Reports Q4 Loss, Lags Revenue Estimates

PTC Therapeutics (PTCT) delivered earnings and revenue surprises of -182.76% and 2.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Bioventus (BVS) to Report Q3 Earnings: What's in the Cards?

On Bioventus' (BVS) third-quarter 2023 earnings call, investors' focus is likely to be on the sales numbers of its three business units - pain treatments, restorative therapies and surgical solutions.

Indrajit Bandyopadhyay headshot

3 Value Medical Stocks to Buy for Safety Amid Market Volatility

We have narrowed our search to three value stocks from the Medical sector. These are PHG, RDNT and BVS.

Zevra Therapeutics (ZVRA) Reports Q1 Loss, Tops Revenue Estimates

Zevra Therapeutics (ZVRA) delivered earnings and revenue surprises of -30.77% and 3.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

AcelRx Pharmaceuticals (ACRX) Reports Break-Even Earnings for Q1

AcelRx Pharmaceuticals (ACRX) delivered earnings and revenue surprises of 100% and 100%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Durect (DRRX) Reports Q1 Loss, Misses Revenue Estimates

Durect (DRRX) delivered earnings and revenue surprises of -4% and 41.81%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for April 5th

BVS, BFAM and ESTE have been added to the Zacks Rank #5 (Strong Sell) List on April 5, 2023.

Journey Medical Corporation (DERM) Reports Q4 Loss, Misses Revenue Estimates

Journey Medical Corporation (DERM) delivered earnings and revenue surprises of -62.16% and 4.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ProPhase Labs, Inc. (PRPH) Reports Q4 Loss, Tops Revenue Estimates

ProPhase Labs, Inc. (PRPH) delivered earnings and revenue surprises of -500% and 6.30%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Lags Revenue Estimates

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -51.85% and 73.36%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Bioventus (BVS) Stock?

Investors need to pay close attention to Bioventus (BVS) stock based on the movements in the options market lately.

4D Molecular Therapeutics, Inc. (FDMT) Reports Q4 Loss, Lags Revenue Estimates

4D Molecular Therapeutics, Inc. (FDMT) delivered earnings and revenue surprises of -12% and 74.90%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Jazz Pharmaceuticals (JAZZ) Reports Q4 Loss, Misses Revenue Estimates

Jazz (JAZZ) delivered earnings and revenue surprises of -113.73% and 0.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Xencor (XNCR) Reports Q4 Loss, Tops Revenue Estimates

Xencor (XNCR) delivered earnings and revenue surprises of 75.90% and 8.61%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates

Aerie (AERI) delivered earnings and revenue surprises of 38.46% and 2.59%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Bioventus (BVS) Stock Options

Investors need to pay close attention to Bioventus (BVS) stock based on the movements in the options market lately.

Company News for Mar 11, 2022

Companies in The News Are: CLVT,BVS,KRO,CRWD

ChemoCentryx (CCXI) Reports Q4 Loss, Lags Revenue Estimates

ChemoCentryx (CCXI) delivered earnings and revenue surprises of -1.75% and 33.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Ardelyx (ARDX) Reports Q4 Loss, Misses Revenue Estimates

Ardelyx (ARDX) delivered earnings and revenue surprises of -24% and 48.55%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

PolarityTE (PTE) Gets FDA Nod to Begin Pivotal Ulcer Study

PolarityTE (PTE) announces removal of clinical hold on a proposed pivotal study to evaluate its SkinTE for chronic cutaneous ulcers. PolarityTE plans to start enrollment in the next few months.

Indrajit Bandyopadhyay headshot

3 Small Biotech Stocks in Focus on World Arthritis Day

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.

Concert (CNCE) Initiates Second Phase III Hair Loss Study

Concert Pharmaceuticals (CNCE) is developing its lead pipeline candidate, CTP-543, for treating alopecia areata. Two late-stage studies are evaluating the candidate in AA patients to support a potential NDA filing.

Will Bioventus (BVS) Continue to Surge Higher?

As of late, it has definitely been a great time to be an investor of Bioventus (BVS).